Evidence map›Paper›PMID 32193697›Full record

ArticleFamilial cancer2020

Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance.

Kasper A Overbeek, Djuna L Cahen, Anne Kamps, Ingrid C A W Konings, Femme Harinck, Marianne A Kuenen, Bas Groot Koerkamp, Marc G Besselink, Casper H van Eijck, Anja Wagner and 9 more

Abstract read
In one paragraph

Article in Familial cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kasper A OverbeekDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. k.overbeek@erasmusmc.nl.ORCID 0000-0003-1829-9963
Djuna L CahenDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Anne KampsDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Ingrid C A W KoningsDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Femme HarinckDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marianne A KuenenDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marc G BesselinkDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Casper H van EijckDepartment of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Anja WagnerDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Margreet G E AusemsDivision Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Manon van der VlugtDepartment of Gastroenterology & Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Paul FockensDepartment of Gastroenterology & Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Frank P VleggaarDepartment of Gastroenterology & Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jan-Werner PoleyDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jeanin E van HooftDepartment of Gastroenterology & Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Eveline M A BleikerDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marco J BrunoDepartment of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Dutch Familial Pancreatic Cancer Surveillance Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In high-risk individuals participating in a pancreatic cancer surveillance program, worrisome features warrant for intensified surveillance or, occasionally, surgery. Our objectives were to determine the patient-reported burden of intensified surveillance and/or surgery, and to assess post-operative quality of life and opinion of surgery. Participants in our pancreatic cancer surveillance program completed questionnaires including the Cancer Worry Scale (CWS) and the Hospital Anxiety and Depression Scale (HADS). For individuals who underwent intensified surveillance, questionnaires before, during, and ≥ 3 weeks after were analyzed. In addition, subjects who underwent intensified surveillance in the past 3 years or underwent surgery at any time, were invited for an interview, that included the Short-Form 12 (SF-12). A total of 31 high-risk individuals were studied. During the intensified surveillance period, median CWS scores were higher (14, IQR 7), as compared to before (12, IQR 9, P = 0.007) and after (11, IQR 7, P = 0.014), but eventually returned back to baseline (P = 0.823). Median HADS scores were low: 5 (IQR 6) for anxiety and 3 (IQR 5) for depression, and they were unaffected by the intensified surveillance period. Of the 10 operated patients, 1 (10%) developed diabetes and 7 (70%) pancreatic exocrine insufficiency. The interviews yielded median quality-of-life scores comparable to the general population. Also, after surgery, patients' attitudes towards surveillance were unchanged (5/10, 50%) or became more positive (4/10, 40%). Although patients were aware of the (sometimes benign) pathological outcome, when asked if surgery had been justified, only 20% (2/10) disagreed, and all would again have chosen to undergo surgery. In conclusion, in individuals at high risk for pancreatic cancer, intensified surveillance temporarily increased cancer worries, without affecting general anxiety or depression. Although pancreatic surgery led to substantial co-morbidity, quality of life was similar to the general population, and surgery did not negatively affect the attitude towards surveillance.

Indexed as

Patient Reported Outcome MeasuresPopulation SurveillanceQuality of LifeAgedAnxietyAttitudeCarcinoma, Pancreatic DuctalDepressionDiabetes MellitusExocrine Pancreatic InsufficiencyFemaleHumansMaleMiddle AgedNetherlandsPancreatic NeoplasmsPancreatic cancerPatient-reported outcome measuresPsychologyQuality of lifeResectionSurveillance

Identifiers

PMID32193697
PMCPMC7242488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.